|
1
|
Salman BN, Muhammad A, Ansari UB, Shah ZU,
Qureshi MF, Ahmad S and Imran R: Evolutionary analysis of influenza
A(H1N1) pdm09 during the pandemic and post-pandemic period in
Pakistan. Trop Biomed. 36:447–458. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Singh P, Sharma K, Bhargava A, Kumar V,
Chawla R, Tiwari M, Yadav S and Gupta N: Genomic characterization
of Influenza A (H1N1) pdm09 and SARS-CoV-2 from influenza like
Illness (ILI) and severe acute respiratory Illness (SARI) cases
reported between July-December 2022. Sci Rep.
14(10660)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Killingley B, Greatorex J, Cauchemez S,
Morgan A and Holmes A: Virus shedding and environmental deposition
of novel A(H1N1) pandemic influenza virus: Interim findings. Health
Technol Assess. 14:237–354. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Influenza A: (H1N1) pdm09 virus: Is it
really ‘new’? Pacini Editore. 25:205–212. 2010.
|
|
5
|
Sullivan SJ, Jacobson RM, Dowdle WR and
Poland GA: 2009 H1N1 influenza. Mayo Clin Proc. 85:64–76.
2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Baldo V, Bertoncello C, Cocchio S, Fonzo
M, Pillon P, Buja A and Baldovin T: The new pandemic influenza
A/(H1N1)pdm09 virus: Is it really ‘new’? J Prev Med Hyg.
57:E19–E22. 2016.PubMed/NCBI
|
|
7
|
Centers for Dicease Control and Prevention
(CDC): Influenza A (H1N1) pdm09 virus. CDC, Atlanta, GA, 2022.
https://www.cdc.gov/flu/professionals/acip/background/references.htm.
|
|
8
|
Jain S, Kamimoto L, Bramley AM, Schmitz
AM, Benoit SR, Louie J, Sugerman DE, Druckenmiller JK, Ritger KA,
Chugh R, et al: Hospitalized patients with 2009 H1N1 influenza in
the United States, April-June 2009. N Engl J Med. 361:1935–1944.
2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Soudani S, Mafi A, Al Mayahi Z, Al Balushi
S, Dbaibo G, Al Awaidy S and Amiche A: A systematic review of
influenza epidemiology and surveillance in the Eastern
Mediterranean and North African region. Infect Dis Ther. 11:15–52.
2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Baldo V, Bertoncello C, Cocchio S, Fonzo
M, Pillon P, Buja A and Baldovin T: The new pandemic influenza
A/(H1N1)pdm09 virus: is it really “new”? J Prev Med Hyg.
57:E19–E22. 2016.PubMed/NCBI
|
|
11
|
Bolton JS, Klim H, Wellens J, Edmans M,
Obolski U and Thompson CP: An antigenic Thrift-based approach to
influenza vaccine design. Vaccines (Basel). 9(657)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liang Y: Pathogenicity and virulence of
influenza. Virulence. 14(2223057)2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Caspard H, Coelingh KL, Mallory RM and
Ambrose CS: Association of vaccine handling conditions with the
effectiveness of live attenuated influenza vaccine against
H1N1pdm09 viruses in the United States. Vaccine. 34:5066–5072.
2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cotter CR, Jin H and Chen Z: A single
amino acid in the stalk region of the H1N1pdm influenza virus HA
protein affects viral fusion, stability, and infectivity. PLoS
Pathog. 10(e1003831)2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pushan SS, Samantaray M, Rajagopalan M and
Ramaswamy A: Evolution of Indian Influenza A (H1N1) Hemagglutinin
Strains: A comparative analysis of the pandemic Californian HA
strain. Front Mol Biosci. 10(1111869)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Dar AM and Mir S: Molecular docking:
Approaches, types, applications and basic challenges. J Anal
Bioanal Tech. 8(356)2017.
|
|
17
|
Daina A, Michielin O and Zoete V:
SwissADME: A free web tool to evaluate pharmacokinetics,
Drug-likeness, and medicinal chemistry friendliness of small
molecules. Sci Rep. 7(42717)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ferreira LG, Dos Santos RN, Oliva G and
Andricopulo AD: Molecular docking and Structure-based drug design
strategies. Molecules. 20:13384–13421. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Meng XY, Zhang H X, Mezei M and Cui M:
Molecular docking: A powerful approach for structure-based drug
discovery. Curr Comput Aided Drug Des. 7:146–157. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zaremba P, Zaremba A, Naumenko K and
Koltsov A: In vitro and in silico studies of the antiviral activity
of polyhydrated fullerenes against influenza A (H1N1) virus. Sci
Rep. 13(10879)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Decker CH, Rapier-Sharman N and Pickett
BE: Mutation in hemagglutinin antigenic sites in Influenza A pH1N1
viruses from 2015-2019 in the United States Mountain West, Europe,
and the Northern Hemisphere. Genes (Basel). 13(909)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang Y, Aevermann BD, Anderson TK, Burke
DF, Dauphin G, Gu Z, He S, Kumar S, Larsen CN, Lee AJ, et al:
Influenza research database: An integrated bioinformatics resource
for influenza virus research. Nucleic Acids Res. 45:D466–D474.
2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mortazavi M, Pirbonyeh N, Javanmardi F and
Emami A: Bioinformatics and structural analysis of antigenic
variation in the hemagglutinin gene of the influenza A(H1N1) pdm09
virus circulating in Shiraz (2013 to 2015). Microbiol Spectr.
11(e0463022)2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ginting TE, Shinya K, Kyan Y, Makino A,
Matsumoto N, Kaneda S and Kawaoka Y: Amino acid changes in
hemagglutinin contribute to the replication of
Oseltamivir-resistant H1N1 influenza viruses. J Virol. 86:121–127.
2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Innocenzi P and Stagi L: Carbon-based
antiviral nanomaterials: Graphene, C-dots, and fullerenes. A
perspective. Chem Sci. 11:6606–6622. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Maleki A, Russo G, Parasiliti Palumbo GA,
Mirjalili A and Angeletti M: In silico design of recombinant
Multi-epitope vaccine against influenza A virus. BMC
Bioinformatics. 22 (Suppl 14)(S617)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hay AJ and McCauley JW: The WHO global
influenza surveillance and response system (GISRS)-A future
perspective. Influenza Other Respir Viruses. 12:551–557.
2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Xu PY, Li XQ, Chen WG, Deng LL, Tan YZ,
Zhang Q, Xie SY and Zheng LS: Progress in antiviral fullerene
research. Nanomaterials (Basel). 12(2547)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Peng S, Wang H, Wang Z and Wang Q:
Progression of antiviral agents targeting viral polymerases.
Molecules. 27(7370)2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sinegubova EO, Kraevaya OA, Volobueva AS,
Zhilenkov AV, Shestakov AF, Baykov SV, Troshin PA and Zarubaev VV:
Water-Soluble Fullerene C60 derivatives are effective
inhibitors of influenza virus replication. Microorganisms.
11(681)2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Dunning J, Baillie JK, Cao B and Hayden
FG: International Severe Acute Respiratory and Emerging Infection
Consortium (ISARIC). Antiviral combinations for severe influenza.
Lancet Infect Dis. 14:1259–1270. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Katagishi D, Yasuda D, Takahashi K,
Nakamura S, Mashino T and Ohe T: Fullerene derivatives as
inhibitors of the SARS-CoV-2 main protease. Bioorg Med Chem Lett.
80(129121)2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sette-DE-Souza PH, Costa MJF, Araújo FAC,
Alencar EN and Amaral Machado L: Two phytocompounds from Schinopsis
brasiliensis show promising antiviral activity with multiple
targets in Influenza A virus. An Acad Bras Cienc. 93 (Suppl
4)(e20210964)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Song X, Li Y, Wu H, Qiu H and Sun Y:
T-cell Epitope-based vaccines: A promising strategy for prevention
of infectious diseases. Vaccines (Basel). 12(1181)2024.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Russo G, Crispino E, Maleki A, Di
Salvatore V, Stanco F and Pappalardo F: Beyond the state of the art
of reverse vaccinology: Predicting vaccine efficacy with the
universal immune system simulator for influenza. BMC
Bioinformatics. 24(231)2023.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Cha Y, Erez T, Reynolds IJ, Kumar D, Ross
J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, et al: Drug
repurposing from the perspective of pharmaceutical companies. Br J
Pharmacol. 175:168–180. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Mtambo SE and Kumalo HM: In silico drug
repurposing of FDA-approved drugs highlighting Promacta as a
potential inhibitor of H7N9 influenza virus. Molecules.
27(4515)2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Xu C, Zhang N, Yang Y, Liang W, Zhang Y,
Wang J, Suzuki Y, Wu Y, Chen Y, Yang H, et al: Immune escape
adaptive mutations in hemagglutinin are responsible for the
antigenic drift of Eurasian Avian-Like H1N1 swine influenza
viruses. J Virol. 96(e0097122)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Nelson MI, Simonsen L, Viboud C, Miller MA
and Holmes EC: The origin and global emergence of adamantane
resistant A/H3N2 influenza viruses. Virology. 388:270–278.
2009.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Briand S, Mounts A and Chamberland M:
Challenges of global surveillance during an influenza pandemic.
Public Health. 125:247–256. 2011.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Batool S, Chokkakula S and Song MS:
Influenza treatment: Limitations of antiviral therapy and
advantages of drug combination therapy. Microorganisms.
11(183)2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Tosh PK, Jacobson RM and Poland GA:
Influenza vaccines: From surveillance through production to
protection. Mayo Clin Proc. 85:257–273. 2010.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Salo-Tuominen K, Teros-Jaakkola T,
Toivonen L, Ollila H, Rautava P, Aromaa M, Lahti E, Junttila N and
Peltola V: Parental socioeconomic and psychological determinants of
the 2009 pandemic influenza A(H1N1) vaccine uptake in children.
Vaccine. 40:3684–3689. 2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
World Health Organization. Ten threats to
global health in 2019. 2019.
|
|
45
|
De Courville C, Cadarette SM, Wissinger E
and Alvarez FP: The economic burden of influenza among adults aged
18 to 64: A systematic literature review. Influenza Other Respir
Viruses. 16:376–385. 2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Lautenbach E, Saint S, Henderson DK and
Harris AD: Initial response of health care institutions to
emergence of H1N1 influenza: Experiences, obstacles, and perceived
future needs. Clin Infect Dis. 50:523–527. 2010.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Liu T, Liu M, Chen F, Chen F, Tian Y,
Huang Q, Liu S and Yang J: A Small-Molecule compound has
Anti-influenza A virus activity by acting as a ‘PB2 Inhibitor’. Mol
Pharm. 15:4110–4120. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
NIAID Collaborative Influenza Vaccine
Innovation Centers (CIVICs): NIAID Strategic Plan for a Universal
Influenza Vaccine. https://www.niaidcivics.org/news/2019/10/niaid-strategic-plan-for-a-universal-influenza-vaccine.
|
|
49
|
Yamayoshi S and Kawaoka Y: Current and
future influenza vaccines. Nat Med. 25:212–220. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Musharrafieh R, Lagarias P, Ma C, Hau R,
Romano A, Lambrinidis G, Kolocouris A and Wang J: Investigation of
the drug resistance mechanism of M2-S31N channel blockers through
biomolecular simulations and viral passage experiments. ACS
Pharmacol Transl Sci. 3:666–675. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Lee RU, Phillips CJ and Faix DJ: Seasonal
influenza vaccine impact on pandemic H1N1 vaccine efficacy. Clin
Infect Dis. 68:1839–1846. 2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Gautam K and Kakade AS: Tackling influenza
A virus by M2 ion channel blockers: Latest progress and
limitations. Eur J Med Chem. 267(116172)2024.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Xu J, Luo Q, Huang Y, Li J, Ye W, Yan R,
Zhou X, He Z, Liu G and Zhu Q: Influenza neuraminidase mutations
and resistance to neuraminidase inhibitors. Emerg Microbes Infect.
13(2429627)2024.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Hayden FG, Lenk RP, Stonis L,
Oldham-Creamer C, Kang LL and Epstein C: Favipiravir treatment of
uncomplicated influenza in adults: Results of two Phase 3,
randomized, Double-blind, Placebo-controlled trials. J Infect Dis.
226:1790–1799. 2022.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Rossignol JF: Nitazoxanide: A
first-in-class broad-spectrum antiviral agent. Antiviral Res.
110:94–103. 2024.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Kiselev OI, Maleev VV, Deeva EG, Leneva
IA, Selkova EP, Osipova EA, Obukhov AA, Nadorov SA and Kulikova EV:
Clinical efficacy of arbidol (umifenovir) in the therapy of
influenza in adults: Preliminary results of the multicenter
Double-blind randomized Placebo-controlled study ARBITR. Ter Arkh.
87:88–96. 2015.PubMed/NCBI View Article : Google Scholar : (In Russian).
|
